A Beijing-based venture capital investor with offices across China and Hong Kong manages $8 billion USD in assets and is currently overseeing multiple funds, including RMB and USD funds. The firm invests across various sectors, with life sciences and healthcare being one of the major focus areas. The firm is capable of investing from early seed to pre-IPO. For early-stage investments, the sweet spot is from Seed to Series B, with average check sizes ranging from $10 million to $20 million USD. Follow-on investments are possible. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. In terms of geographic focus, the firm primarily targets opportunities based in the United States and China.
The firm is most interested in biotech therapeutics or drugs and is open to various modalities such as cell therapies, antibodies, small molecules, and more. The firm is open to considering different indications, with preferences for solid tumors and autoimmune diseases. It prefers assets that are close to the IND phase or, at the very least, have obtained partial proof of concept. The firm is also open to considering medical instruments but typically focuses on companies at a later stage, generating revenue or profits.
The firm does not have specific requirements for management teams but prefers teams with strong backgrounds and successful track records.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment